A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90 <; 5 µm and Dv50<; 1 µm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.